(NASDAQ: STOK) Stoke Therapeutics's forecast annual revenue growth rate of -0.11% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Stoke Therapeutics's revenue in 2025 is $36,555,000.On average, 5 Wall Street analysts forecast STOK's revenue for 2025 to be $3,618,774,138, with the lowest STOK revenue forecast at $324,466,434, and the highest STOK revenue forecast at $9,788,070,759. On average, 2 Wall Street analysts forecast STOK's revenue for 2026 to be $2,316,690,339, with the lowest STOK revenue forecast at $865,243,824, and the highest STOK revenue forecast at $3,768,136,854.
In 2027, STOK is forecast to generate $2,115,142,606 in revenue, with the lowest revenue forecast at $865,243,824 and the highest revenue forecast at $3,890,352,544.